Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MPH.0000000000001943 http://scihub22266oqcxt.onion/10.1097/MPH.0000000000001943 32925396!?!32925396 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32925396&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Pediatr+Hematol+Oncol 2021 ; 43 (6): e804-e807 Nephropedia Template TP {{tp|p=32925396|t=2021. SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia |pdf=|usr=}}{{32925396}} gab.com Text SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia JO: J Pediatr Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=32925396 #FOAvip The clinical course of SARS-CoV-2 infection (COVID-19) in children with hematologic malignancies is unclear. We describe the diagnosis, treatment and outcome of a 4-year-old boy with high-risk acute lymphoblastic leukemia and COVID-19. Regardless of immunosuppressive induction chemotherapy his symptoms remained moderate. He received only supportive treatment. Seroconversion occurred in a similar period as in immunocompetent adults. Despite prolonged myelosuppression he did neither acquire secondary infections nor did the treatment delay caused by the infection have a measurable negative impact on the residual disease of acute lymphoblastic leukemia. Intriguingly, residual leukemia even decreased even though he did not receive any antileukemic therapy. Twit Text FOAVip SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia ????J Pediatr Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=32925396 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32925396 #FOAvip English Wikipedia <ref>{{Cite pmid|32925396}}</ref> SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia #MMPMID32925396 Dantonello TM; Kartal-Kaess M; Aebi C; Suter-Riniker F; Busch JD; Kubetzko S; Bourquin JP; Roessler J J Pediatr Hematol Oncol 2021[Aug]; 43 (6): e804-e807 PMID32925396show ga The clinical course of SARS-CoV-2 infection (COVID-19) in children with hematologic malignancies is unclear. We describe the diagnosis, treatment and outcome of a 4-year-old boy with high-risk acute lymphoblastic leukemia and COVID-19. Regardless of immunosuppressive induction chemotherapy his symptoms remained moderate. He received only supportive treatment. Seroconversion occurred in a similar period as in immunocompetent adults. Despite prolonged myelosuppression he did neither acquire secondary infections nor did the treatment delay caused by the infection have a measurable negative impact on the residual disease of acute lymphoblastic leukemia. Intriguingly, residual leukemia even decreased even though he did not receive any antileukemic therapy. |COVID-19/*complications/virology[MESH] |Child, Preschool[MESH] |Humans[MESH] |Induction Chemotherapy/*methods[MESH] |Male[MESH] |Neoplasm, Residual/*prevention & control[MESH] |Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/pathology/virology[MESH]SARS-CoV-2 Infection During Induction Chemotherapy in a Child With Hig(epmc).pdf DeepDyve Pubget Overpricing